Compare McKesson Corporation (MCK) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? McKesson Corporation trades at $823.64 (market cap $97.35B), while iShares 20 Plus Year Treasury Bond ETF trades at $83.65. The key difference: McKesson Corporation pays a 0.39% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and McKesson Corporation is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| MCK | TLT | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | — |
52-Week High | $995.69 | $92.06 |
52-Week Low | $659.01 | $83.02 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $83.89, down 0.75% on the day. Technical indicators signal a bearish trend with moving averages showing selling pressure, while oscillators are neutral. The ETF has faced significant outflows amid rising interest rate concerns, with recent articles highlighting competition from cash ETFs and corporate bond alternatives offering higher yields. Dividend payments remain consistent but modest.
The outlook for TLT hinges on Federal Reserve policy shifts; potential rate cuts could boost long-term bonds, but persistent inflation risks may extend volatility. Investors face duration risk and opportunity cost versus shorter-term instruments. Wall Street sentiment is mixed, with some seeing value at current yields after steep declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
